Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
-9.1%
Buyback spend (TTM)
N/A
Cumulative buybacks
$38.32B
Key takeaways
- Diluted share count is down 9.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Biogen (BIIB)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Biogen (BIIB)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Biogen (BIIB)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Biogen (BIIB)
Latest: $0.00
Overview
2025's annual buyback spend for Biogen (BIIB) came in at $0.00.
Through 2020–2025 (5 years), Biogen buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Between 2020 and 2025, Biogen buyback spend plunged 100.0%, falling from $6.68B to $0.00.
The record annual buyback spend stands at $6.68B, reached in 2020; the historical low of $0.00 was recorded in 1989.
Biogen Buyback Spend 2025: $0.00
Biogen buyback spend in 2025 was $0.00.
Biogen Buyback Spend 2024: $0.00
Biogen buyback spend in 2024 was $0.00.
Biogen Buyback Spend 2023: $0.00
In 2023, Biogen reported buyback spend of $0.00, plunged 100.0% below 2022.
Biogen Buyback Spend 2022: $750.00M
Biogen buyback spend in 2022 was $750.00M, plunged 58.3% below 2021.
Biogen Buyback Spend 2021: $1.80B
Biogen buyback spend in 2021 was $1.80B.
See more financial history for Biogen (BIIB).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $290.80M | −$290.80M | — | 0.15B | +0.5% | |
| 2024 | $0.00 | $291.20M | −$291.20M | — | 0.15B | +0.2% | |
| 2023 | $0.00 | $264.20M | −$264.20M | — | 0.15B | -0.3% | |
| 2022 | $750.00M | $254.10M | $495.90M | 1.88% | 0.15B | -2.4% | |
| 2021 | $1.80B | $238.60M | $1.56B | 5.11% | 0.15B | -7.3% | |
| 2020 | $6.68B | $198.30M | $6.48B | 17.75% | 0.16B | -13.9% | |
| 2019 | $5.87B | $182.30M | $5.69B | 11.12% | 0.19B | -8.7% | |
| 2018 | $4.35B | $157.50M | $4.20B | 7.24% | 0.21B | -3.6% | |
| 2017 | $1.37B | $128.00M | $1.24B | 2.03% | 0.21B | -2.7% | |
| 2016 | $1.00B | $154.80M | $845.20M | 1.63% | 0.22B | -5.4% | |
| 2015 | $5.00B | $161.40M | $4.84B | 7.41% | 0.23B | -2.5% | |
| 2014 | $886.78M | $155.30M | $731.48M | 1.11% | 0.24B | -0.5% | |
| 2013 | $400.31M | $136.29M | $264.02M | 0.61% | 0.24B | -0.6% | |
| 2012 | $984.72M | $118.57M | $866.15M | 2.84% | 0.24B | -2.2% | |
| 2011 | $497.98M | $113.00M | $384.97M | 1.86% | 0.25B | -3.9% | |
| 2010 | $2.08B | $167.83M | $1.91B | 12.83% | 0.25B | -12.0% | |
| 2009 | $751.17M | $160.90M | $590.27M | 5.20% | 0.29B | -1.9% | |
| 2008 | $738.94M | $146.21M | $592.73M | 5.39% | 0.29B | -7.9% | |
| 2007 | $2.99B | $123.13M | $2.87B | 17.74% | 0.32B | -7.3% | |
| 2006 | $320.27M | $126.78M | $193.49M | 1.91% | 0.35B | -0.3% | |
| 2005 | $322.59M | $38.15M | $284.44M | 2.10% | 0.35B | +0.8% | |
| 2004 | $734.43M | $16.80M | $717.63M | 3.29% | 0.34B | +2.9% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 0.33B | -16.3% | |
| 2002 | $135.00M | $2.36M | $132.64M | 1.04% | 0.40B | 0.0% | |
| 2001 | $88.28M | $0.00 | $88.28M | 0.33% | 0.40B | -14.0% | |
| 2000 | $300.19M | $0.00 | $300.19M | — | 0.46B | -2.0% | |
| 1999 | $197.72M | $0.00 | $197.72M | — | 0.47B | -49.9% | |
| 1998 | $65.55M | $0.00 | $65.55M | — | 0.95B | +2.0% | |
| 1997 | $7.00M | $0.00 | $7.00M | — | 0.93B | +0.4% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.92B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1989 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$750.00M
- 2021$1.80B
- 2020$6.68B
- 2019$5.87B
- 2018$4.35B
- 2017$1.37B
- 2016$1.00B
- 2015$5.00B
- 2014$886.78M
- 2013$400.31M
- 2012$984.72M
- 2011$497.98M
- 2010$2.08B
- 2009$751.17M
- 2008$738.94M
- 2007$2.99B
- 2006$320.27M
- 2005$322.59M
- 2004$734.43M
- 2003$0.00
- 2002$135.00M
- 2001$88.28M
- 2000$300.19M
- 1999$197.72M
- 1998$65.55M
- 1997$7.00M
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
- 1990$0.00
- 1989$0.00
Buybacks vs stock-based compensation for Biogen (BIIB)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Biogen (BIIB)
How Biogen splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Biogen, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $2.62B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation